SnapShot: Kinase Inhibitors II.

SnapShot: Kinase Inhibitors I.

Covalent-Allosteric Kinase Inhibitors.

Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).

Template-based de novo design for type II kinase inhibitors and its extented application to acetylcholinesterase inhibitors.

2 kinase inhibitors.

Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase.

Copolymers of glutamic acid and tyrosine are potent inhibitors of oocyte casein kinase II.

Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.

Tirosine kinase inhibitors adverse events.

Pharmacology of protein kinase inhibitors.

Tyrosine kinase inhibitors and pregnancy.

Kinase inhibitors overachieve in CLL.

Tyrosine kinase inhibitors and interferon.

Targeting cancer with kinase inhibitors.

Nucleoside inhibitors of rhodopsin kinase.

Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors.

SnapShot: Macroautophagy.

Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.

SnapShot: Medulloblastoma.

SnapShot: Immunometabolism.

Crystallographic snapshot of the Escherichia coli EnvZ histidine kinase in an active conformation.

Calmodulin-dependent protein kinase II.

Ocular Toxicity of Tyrosine Kinase Inhibitors.

Aurora Kinase Inhibitors: Current Status and Outlook.

Suggest Documents

SnapShot: Kinase Inhibitors I.

Covalent-Allosteric Kinase Inhibitors.

Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2).

Template-based de novo design for type II kinase inhibitors and its extented application to acetylcholinesterase inhibitors.

2 kinase inhibitors.

Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase.

Copolymers of glutamic acid and tyrosine are potent inhibitors of oocyte casein kinase II.

Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors.

Tirosine kinase inhibitors adverse events.

Pharmacology of protein kinase inhibitors.

Tyrosine kinase inhibitors and pregnancy.

Kinase inhibitors overachieve in CLL.

Tyrosine kinase inhibitors and interferon.

Targeting cancer with kinase inhibitors.

Nucleoside inhibitors of rhodopsin kinase.

Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors.

SnapShot: Macroautophagy.

Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors.

SnapShot: Medulloblastoma.

SnapShot: Immunometabolism.

Crystallographic snapshot of the Escherichia coli EnvZ histidine kinase in an active conformation.

Calmodulin-dependent protein kinase II.

Ocular Toxicity of Tyrosine Kinase Inhibitors.

Aurora Kinase Inhibitors: Current Status and Outlook.

SnapShot: Kinase Inhibitors II.

Recommend Documents

Follow Us